| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Science in Renal Medicine |


* Division of Pediatric Nephrology, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, and
Division of Nephrology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Correspondence: Dr. Mitchell L. Halperin, Department of Medicine, University of Toronto, St. Michael's Hospital Annex, Lab #1, Research Wing, 38 Shuter Street, Toronto, Ontario, M5B 1A6, Canada. Phone: 416-864-5292; Fax: 416-864-5943; E-mail: mitchell.halperin{at}utoronto.ca
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
We explore a different way to analyze the buffering of a H+ load and suggest that a "brain protein–centered" view may lead to a better understanding of the pathophysiology, with important implications for therapy. Its major tenet is that buffering not only should diminish the rise in the H+ concentration but also should do so while minimizing the binding of H+ to proteins in cells of the brain (equation 1). If extra H+ bind to proteins, then this will make their "ideal or native" net valence (Protein°) become more cationic or less anionic (H·Protein+)2 and alter their shape and possibly their function (as enzymes, transporters, contractile elements, and structural compounds).3
![]() | (1) |
The bicarbonate (HCO3–) buffer system (BBS) is the most important physiologic buffer because it can remove H+ without requiring a high H+ concentration and thereby avoids a change in protein net charge.4 Therefore, we examine the properties to ensure that the BBS and not the proteins will remove the bulk of added H+.
The BBS can out-compete the proteins for H+ removal mainly because acidemia stimulates ventilation, which lowers the Pco2 (Figure 1 and equation 2). As a result, H+ are forced to react with HCO3–, and the concentration of both reactants will decrease in a 1:1 ratio. Notwithstanding, the percentage decline in the H+ concentration is much larger than that of HCO3– because the former is approximately 106-fold lower than the latter. In addition, the BBS is very effective because the content of HCO3– in the body is large (approximately 375 mmol in the extracellular fluid (ECF) [25 mM x 15 L] and intracellular fluid (ICF) [12.5 mM x 30 L] compartments in a 70-kg adult).
![]() | (2) |
|
Only red blood cells, while in the arterial compartment, have the same Pco2 as in arterial blood because all other organs consume oxygen and add CO2 to their capillary blood (Table 1). Because CO2 diffuses rapidly, distances are short, and time is not a limiting factor, the Pco2 in capillaries is virtually identical to the Pco2 in cells; this is also true for the interstitial compartment of the ECF in this region. Therefore, the arterial Pco2 does not reveal whether the BBS has operated efficiently in the vast majority of the ICF and ECF compartments; notwithstanding, the arterial Pco2 sets the lower limit for the Pco2 in capillaries.
|
The focus should be on skeletal muscle because it has the largest content of HCO3–. If this organ requires a high H+ concentration to remove the bulk of the H+ load during metabolic acidosis (Figure 1, bottom left), then the resultant increase in acidemia will force more H+ to bind to intracellular proteins in the brain (Figure 1, bottom right).6
At the usual rates of CO2 production and with usual blood flow rates at rest, the brachial venous Pco2 is approximately 46 mmHg when the arterial Pco2 is 40 mmHg. The Pco2 in venous blood draining skeletal muscle will be much higher than the arterial Pco2 in two circumstances: (1) if more oxygen is consumed and the rate of blood flow does not rise by an commensurate amount (e.g., during vigorous exercise) and (2) if the rate of blood flow falls and there is no major decline in the rate of consumption of oxygen.2 The main cause of failure of the BBS in skeletal muscle is a marked decline in its blood flow when metabolic acidosis is accompanied by a contracted effective arterial blood volume.6–9
Turning our attention to therapy with NaHCO3 for metabolic acidosis, it is not our intention to discuss the controversy about NaHCO3 therapy for patients with metabolic acidosis who in fact represent a heterogeneous group; rather, we address this topic from a brain protein–centered perspective.
There are circumstances in which NaHCO3 must be administered at the outset. For example, patients who have metabolic acidosis, a very contracted ECF volume, and large diarrhea losses require therapy with NaHCO3 because their plasma HCO3– concentration will fall by dilution, the intestinal loss of NaHCO3 will be augmented when splanchnic perfusion improves,10 and the ability to add new HCO3– by metabolism of organic anions or the excretion of NH4+ cannot occur at a sufficiently rapid rate. In fact, there was a higher mortality rate in these patients when therapy did not include the administration of NaHCO3.11,12
The most important goal is to reduce the number of H+ bound to proteins in brain cells. To achieve this objective, the Pco2 in veins draining skeletal muscle must fall. Two events permit this to occur: (1) Lowering the arterial Pco2 if this value is inappropriately high for the degree of acidemia10 and (2) improving hemodynamics by infusing saline if the patient has a low ECF volume. One can follow the effectiveness of therapy to achieve this aim by examining serial changes in the venous Pco2.9
One should not assess the effectiveness of NaHCO3 therapy solely by the rise in the plasma HCO3– concentration. In more detail, if the administered HCO3– were titrated by H+ bound to proteins in cells, then failure to see a rise in this HCO3– concentration when NaHCO3 is administered could be beneficial because proteins now have a less net positive charge. An example of this improvement could be de-inhibition of the key glycolytic enzyme phosphofructokinase when the intracellular pH rises in myocardial cells.13 If the rate of anaerobic glycolysis were to increase the administration of NaHCO3, then this could be viewed as detrimental if one considers only the H+ and l-lactate concentrations. However, if part of lactic acid formation occurred in cardiac myocytes and this led to an increased formation of ATP,14 then the increased energetics may improve the cardiac contractility and thereby improve the cerebral blood flow rate.
Viewed from the brain-centered perspective, calculation of the dosage of NaHCO3 on the basis of the bicarbonate distribution space has a number of limitations. First, this calculation is based on the concentration of HCO3–, not on its content in the ECF compartment.15 Importantly, it considers only the HCO3– that is retained to raise the HCO3– concentration by a certain amount, whereas a "better" HCO3– may be one that was consumed by removing a protein-bound H+. Moreover, this distribution space will depend on how effective the therapy was to lower the venous Pco2 in skeletal muscles.
In conclusion, changing from a proton-centered to a brain protein–centered view of buffering highlights the importance of the physiology of the BBS. To do so, one must also measure the Pco2 in brachial venous blood.15 These new insights may permit improved design for therapy of individual patients with metabolic acidosis.
| DISCLOSURES |
|---|
|
|
|---|
| Footnotes |
|---|
| REFERENCES |
|---|
|
|
|---|
Related Article
This article has been cited by other articles:
![]() |
M. Gowrishankar, A.P.C.P. Carlotti, C. St George-Hyslop, D. Bohn, K.S. Kamel, M.R. Davids, and M.L. Halperin Uncovering the basis of a severe degree of acidemia in a patient with diabetic ketoacidosis QJM, November 1, 2007; 100(11): 721 - 735. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |